Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
129 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Uveitis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Uveitis - Pipeline Review, H2 2014', provides an overview of the Uveitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Uveitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Uveitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Uveitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Uveitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Uveitis Overview 9 Therapeutics Development 10 Pipeline Products for Uveitis - Overview 10 Pipeline Products for Uveitis - Comparative Analysis 11 Uveitis - Therapeutics under Development by Companies 12 Uveitis - Therapeutics under Investigation by Universities/Institutes 14 Uveitis - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Uveitis - Products under Development by Companies 18 Uveitis - Products under Investigation by Universities/Institutes 19 Uveitis - Companies Involved in Therapeutics Development 20 pSivida Corp. 20 Advanced Cell Technology, Inc. 21 Santen Pharmaceutical Co., Ltd. 22 Apitope International NV 23 Novartis AG 24 Pfizer Inc. 25 Enzo Biochem, Inc. 26 Can-Fite BioPharma Ltd. 27 XOMA Corporation 28 HanAll Biopharma Co., Ltd. 29 TxCell SA 30 Endocyte, Inc. 31 to-BBB technologies BV 32 Janssen Biotech, Inc. 33 Icon Bioscience, Inc. 34 Eleven Biotherapeutics 35 AbbVie Inc. 36 OncoNOx ApS 37 Panoptes Pharma Ges.m.b.H. 38 Uveitis - Therapeutics Assessment 39 Assessment by Monotherapy Products 39 Assessment by Target 40 Assessment by Mechanism of Action 43 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 sirolimus - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 adalimumab - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 fluocinolone acetonide - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 gevokizumab - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 secukinumab - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 CF-101 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 triamcinolone acetonide - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 LFG-316 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 B27-PD - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 triamcinolone acetonide - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 celecoxib - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 HL-036 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 EC-1496 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 PA-2612 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 2B3-201 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 ATX-UV1 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 ATX-UV2 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 OX-1001 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 P-13 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 IBI-70090 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 plastoquinone decyl triphenylphosphonium bromide - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 EC-1669 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 lodamin - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 PP-001 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 INV-17 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 EBI-028 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Col-Treg - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Small Molecules to Inhibit Kinase for Uveitis and IBD - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disorders - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Uveitis - Recent Pipeline Updates 96 Uveitis - Dormant Projects 120 Uveitis - Discontinued Products 121 Uveitis - Product Development Milestones 122 Featured News & Press Releases 122 May 20, 2014: AbbVie Receives Orphan Drug Designation for HUMIRA from the U.S. Food and Drug Administration for the Investigational Treatment of Certain Forms of Non-infectious Uveitis 122 Apr 04, 2014: Santen Phase III Study Meets Primary Endpoint for the Treatment of Non-Infectious Posterior Segment Uveitis 122 Feb 24, 2014: XOMA Receives Orphan Drug Designation From U.S. FDA for Pyoderma Gangrenosum 123 Jan 07, 2014: TxCell enters Col-Treg into Full Development for the rare disease Autoimmune Uveitis 123 Oct 18, 2013: Alimera Sciences Receives Complete Response Letter For ILUVIEN 124 Jul 16, 2013: OphthaliX to Initiate a Phase II study of CF101 for the Treatment of Uveitis 125 Mar 14, 2013: Mitotech completes series of uveitis studies 125 Jan 10, 2013: Clearside Biomedical Announces Plans For Clinical Testing Of CLS1001 Suprachoroidal Injectable Suspension For Treatment Of Some Eye Diseases 125 Dec 27, 2012: Isotechnika Announces Voclosporin Fails To Meet Primary Endpoint In Phase III Uveitis Study 126 Oct 03, 2012: Xoma Initiates Phase III Study Of Gevokizumab In Patients With Non-Infectious Uveitis Currently Controlled By Systemic Treatment 126 Appendix 128 Methodology 128 Coverage 128 Secondary Research 128 Primary Research 128 Expert Panel Validation 128 Contact Us 129 Disclaimer 129
List of Tables Number of Products under Development for Uveitis, H2 2014 10 Number of Products under Development for Uveitis - Comparative Analysis, H2 2014 11 Number of Products under Development by Companies, H2 2014 13 Number of Products under Investigation by Universities/Institutes, H2 2014 14 Comparative Analysis by Late Stage Development, H2 2014 15 Comparative Analysis by Clinical Stage Development, H2 2014 16 Comparative Analysis by Early Stage Development, H2 2014 17 Products under Development by Companies, H2 2014 18 Products under Investigation by Universities/Institutes, H2 2014 19 Uveitis - Pipeline by pSivida Corp., H2 2014 20 Uveitis - Pipeline by Advanced Cell Technology, Inc., H2 2014 21 Uveitis - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2014 22 Uveitis - Pipeline by Apitope International NV, H2 2014 23 Uveitis - Pipeline by Novartis AG, H2 2014 24 Uveitis - Pipeline by Pfizer Inc., H2 2014 25 Uveitis - Pipeline by Enzo Biochem, Inc., H2 2014 26 Uveitis - Pipeline by Can-Fite BioPharma Ltd., H2 2014 27 Uveitis - Pipeline by XOMA Corporation, H2 2014 28 Uveitis - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 29 Uveitis - Pipeline by TxCell SA, H2 2014 30 Uveitis - Pipeline by Endocyte, Inc., H2 2014 31 Uveitis - Pipeline by to-BBB technologies BV, H2 2014 32 Uveitis - Pipeline by Janssen Biotech, Inc., H2 2014 33 Uveitis - Pipeline by Icon Bioscience, Inc., H2 2014 34 Uveitis - Pipeline by Eleven Biotherapeutics, H2 2014 35 Uveitis - Pipeline by AbbVie Inc., H2 2014 36 Uveitis - Pipeline by OncoNOx ApS, H2 2014 37 Uveitis - Pipeline by Panoptes Pharma Ges.m.b.H., H2 2014 38 Assessment by Monotherapy Products, H2 2014 39 Number of Products by Stage and Target, H2 2014 42 Number of Products by Stage and Mechanism of Action, H2 2014 45 Number of Products by Stage and Route of Administration, H2 2014 47 Number of Products by Stage and Molecule Type, H2 2014 49 Uveitis Therapeutics - Recent Pipeline Updates, H2 2014 96 Uveitis - Dormant Projects, H2 2014 120 Uveitis - Discontinued Products, H2 2014 121
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
